| Patient | Benny Leonard |
|---|---|
| Date of birth | 1976-04-07 |
| Identifiers | MRN HR-BX008-SYN; SSN (made up) 000-08-4106 |
| Document date | 2026-11-01 |
| Author | Miriam Okafor-Rosenthal, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care at 50 after a referee's license examination found high blood pressure: exertional breathlessness and chest tightness while refereeing, an ECG showing left ventricular hypertrophy, cardiovascular risk, money worries and mood, and a cardiology consultation. Concerns: Breathless and tight in the chest late in long nights in the ring, and told his blood pressure is high; He needs his refereeing work and is afraid of losing his license; Worry about money since losing his savings years ago, and about the cost of medicines. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Losartan 50 mg with hydrochlorothiazide 12.5 mg, one tablet each morning | One tablet each morning | Oral route | 2026-05-12 to 2026-06-30 | completed | S |
| Losartan 100 mg with hydrochlorothiazide 25 mg, one tablet each morning | One tablet each morning; held from the sick visit; stopped at the preventive visit | Oral route | 2026-06-30 to 2026-07-28 | stopped | S |
| Atorvastatin 40 mg tablet, one each evening | One tablet each evening | Oral route | 2026-05-26 | active | S |
| Losartan 100 mg tablet, one each morning | One tablet each morning; hold on sick days | Oral route | 2026-07-28 | active | S |
| Amlodipine 5 mg tablet, one each morning | One tablet each morning | Oral route | 2026-07-28 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Resting 12-lead ECG: sinus rhythm at 78 per minute; left ventricular hypertrophy by voltage (Sokolow-Lyon 38 mm, Cornell 24 mm) with mild lateral T-wave flattening; PR 160 ms; QRS 96 ms; QTc 418 ms; no Q waves, pre-excitation, conduction block or Brugada pattern | 2026-05-12 to 2026-05-12 | completed | S |
| Transthoracic echocardiogram: concentric left ventricular hypertrophy (septum 13 mm, posterior wall 12 mm, septal-to-posterior ratio 1.1, mass index 118 g/m2); ejection fraction 62% without regional wall motion abnormality; grade 1 diastolic dysfunction; left atrial volume index 36 mL/m2; no systolic anterior motion of the mitral valve or outflow tract obstruction at rest or with Valsalva; normal valves; aortic root 34 mm | 2026-05-26 to 2026-05-26 | completed | S |
| Exercise stress echocardiogram (Bruce protocol): 9 minutes 30 seconds, about 10.5 METs; peak heart rate 156 per minute (92% of predicted); blood pressure 150/92 at rest rising to 226/98 mmHg at peak, an exaggerated response; mild breathlessness at peak without chest discomfort; no ST-segment change; no arrhythmia; normal augmentation of all wall segments, with no inducible ischemia | 2026-05-26 to 2026-05-26 | completed | S |
| Noncontrast CT of the heart for coronary calcium: Agatston score 186 (left anterior descending 118, right coronary 52, circumflex 16), about the 80th percentile for his age and sex; no other cardiac finding | 2026-05-26 to 2026-05-26 | completed | S |
| Resting 12-lead ECG at the sick visit: sinus tachycardia at 104 per minute; left ventricular hypertrophy by voltage, unchanged; QTc 432 ms; no ischemic change or arrhythmia | 2026-07-21 to 2026-07-21 | completed | S |
| Advance care planning conversation, about 15 minutes, with his consent | 2026-07-28 to 2026-07-28 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-07-28 | Pneumococcal conjugate vaccine PCV20, single dose, recommended for all adults 50 and older | completed | S |
| 2026-07-28 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-08-25 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2, after a screening panel showed no immunity | completed | S |
| 2026-10-27 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 2026-10-27 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
| 2026-10-27 | Influenza vaccine, inactivated trivalent, this season's formulation | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
No historical medical events are recorded.
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Breathless and tight in the chest late in long nights in the ring, and told his blood pressure is high | active | S |
| He needs his refereeing work and is afraid of losing his license | active | S |
| Worry about money since losing his savings years ago, and about the cost of medicines | active | S |
Most recent measures: Sodium [Moles/volume] in Serum or Plasma 140 on 2026-08-25; Potassium [Moles/volume] in Serum or Plasma 4.4 on 2026-08-25; Urea nitrogen [Mass/volume] in Serum or Plasma 15 on 2026-08-25; Creatinine [Mass/volume] in Serum or Plasma 1.02 on 2026-08-25; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 88 on 2026-08-25; Glucose [Mass/volume] in Serum or Plasma 93 on 2026-08-25; Hemoglobin [Mass/volume] in Blood 14.6 on 2026-05-12; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 2026-05-12; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 2026-05-12; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-05-12; Albumin/Creatinine [Mass Ratio] in Urine 22 on 2026-05-12; Cholesterol [Mass/volume] in Serum or Plasma 138 on 2026-07-28; Cholesterol in HDL [Mass/volume] in Serum or Plasma 47 on 2026-07-28; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 66 on 2026-07-28; Triglyceride [Mass/volume] in Serum or Plasma 124 on 2026-07-28; Lipoprotein a [Moles/volume] in Serum or Plasma 42 on 2026-05-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 2026-10-27; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 3 on 2026-10-27; Total score [AUDIT-C] 2 on 2026-05-12; Left ventricular Ejection fraction 62 on 2026-05-26; Interventricular septum Thickness during diastole by US 13 on 2026-05-26; Left ventricular Myocardial mass/Body surface area [Mass/Area] by US 2D 118 on 2026-05-26; Left atrial End-systolic volume (by US.2D+Calculated by biplane method of disks)/Body surface area 36 on 2026-05-26; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-07-28 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness and tightness across the chest on exertion for about two months, late in long nights of refereeing in hot arenas, easing within a few minutes of rest; never at rest; no fainting, palpitations, orthopnea or ankle swelling; cause under evaluation with a cardiology consultation | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to his documented work as a referee; superseded at the consultation when stress testing showed no ischemia and the symptom was attributed to hypertensive heart disease. |
| Stage 2 hypertension found at a yearly fitness examination for his referee's license (164/100 and 160/98 mmHg), with left ventricular hypertrophy by voltage on the ECG; untreated; home readings to follow | resolved | confirmed | I10 | S — Synthetic diagnosis at intake; reclassified as hypertensive heart disease after the echocardiogram at the consultation. |
| Hypertensive heart disease without heart failure: concentric left ventricular hypertrophy (septum 13 mm, mass index 118 g/m2) with normal ejection fraction, grade 1 diastolic dysfunction, a mildly enlarged left atrium and an exaggerated blood pressure rise on exercise; no features of hypertrophic cardiomyopathy | active | confirmed | I11.9 | S — Synthetic diagnosis made at the cardiology consultation; not a claim about his real heart. |
| Coronary atherosclerosis found by coronary calcium scoring (Agatston score 186, about the 80th percentile for his age and sex), without angina and with no inducible ischemia on exercise stress echocardiography | active | confirmed | I25.10 | S — Synthetic diagnosis made at the cardiology consultation; not a retrospective diagnosis of the cause of his death, which is disputed. |
| Hypercholesterolemia: LDL 160 mg/dL, HDL 44 mg/dL, lipoprotein(a) not raised; no diabetes | active | confirmed | E78.00 | S — Synthetic diagnosis at intake. |
| Volume depletion after refereeing a long card in a heat wave while taking losartan 100 mg with hydrochlorothiazide 25 mg: lightheaded on standing, with an orthostatic fall in blood pressure, a prerenal rise in creatinine to 1.44 mg/dL and potassium 3.3 mmol/L; no fainting, chest pain or arrhythmia | resolved | confirmed | E86.0 | S — Synthetic acute problem from the thiazide in summer heat; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-12 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-146 mmol/L | Normal | S |
| 2026-05-12 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.3 mmol/L | Normal | S |
| 2026-05-12 | Urea nitrogen [Mass/volume] in Serum or Plasma | 15 | mg/dL | 7-25 mg/dL | Normal | S |
| 2026-05-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-05-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 93 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-12 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 65-99 mg/dL | Normal | S |
| 2026-05-12 | Hemoglobin [Mass/volume] in Blood | 14.6 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-05-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 2026-05-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 2026-05-12 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-05-12 | Albumin/Creatinine [Mass Ratio] in Urine | 22 | mg/g{creat} | <=29 mg/g{creat} | Normal | S |
| 2026-05-12 | Cholesterol [Mass/volume] in Serum or Plasma | 234 | mg/dL | <=199 mg/dL | High | S |
| 2026-05-12 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-05-12 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 160 | mg/dL | <=99 mg/dL | High | S |
| 2026-05-12 | Triglyceride [Mass/volume] in Serum or Plasma | 150 | mg/dL | <=149 mg/dL | High | S |
| 2026-05-12 | Lipoprotein a [Moles/volume] in Serum or Plasma | 42 | nmol/L | <=124 nmol/L | Normal | S |
| 2026-05-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-05-12 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 2026-05-12 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 2026-05-26 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-146 mmol/L | Normal | S |
| 2026-05-26 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.3 mmol/L | Normal | S |
| 2026-05-26 | Urea nitrogen [Mass/volume] in Serum or Plasma | 16 | mg/dL | 7-25 mg/dL | Normal | S |
| 2026-05-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-05-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-26 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 65-99 mg/dL | Normal | S |
| 2026-05-26 | Left ventricular Ejection fraction | 62 | % | 52-72% | Normal | S |
| 2026-05-26 | Interventricular septum Thickness during diastole by US | 13 | mm | 6-10 mm | High | S |
| 2026-05-26 | Left ventricular Myocardial mass/Body surface area [Mass/Area] by US 2D | 118 | g/m2 | 49-115 g/m2 | High | S |
| 2026-05-26 | Left atrial End-systolic volume (by US.2D+Calculated by biplane method of disks)/Body surface area | 36 | mL/m2 | 16-34 mL/m² | High | S |
| 2026-06-30 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-146 mmol/L | Normal | S |
| 2026-06-30 | Potassium [Moles/volume] in Serum or Plasma | 3.9 | mmol/L | 3.5-5.3 mmol/L | Normal | S |
| 2026-06-30 | Urea nitrogen [Mass/volume] in Serum or Plasma | 17 | mg/dL | 7-25 mg/dL | Normal | S |
| 2026-06-30 | Creatinine [Mass/volume] in Serum or Plasma | 1.06 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-06-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-30 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 65-99 mg/dL | Normal | S |
| 2026-07-21 | Sodium [Moles/volume] in Serum or Plasma | 133 | mmol/L | 135-146 mmol/L | Low | S |
| 2026-07-21 | Potassium [Moles/volume] in Serum or Plasma | 3.3 | mmol/L | 3.5-5.3 mmol/L | Low | S |
| 2026-07-21 | Urea nitrogen [Mass/volume] in Serum or Plasma | 32 | mg/dL | 7-25 mg/dL | High | S |
| 2026-07-21 | Creatinine [Mass/volume] in Serum or Plasma | 1.44 | mg/dL | 0.7-1.3 mg/dL | High | S |
| 2026-07-21 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 57 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-07-21 | Glucose [Mass/volume] in Serum or Plasma | 104 | mg/dL | 65-99 mg/dL | High | S |
| 2026-07-28 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-146 mmol/L | Normal | S |
| 2026-07-28 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.3 mmol/L | Normal | S |
| 2026-07-28 | Urea nitrogen [Mass/volume] in Serum or Plasma | 17 | mg/dL | 7-25 mg/dL | Normal | S |
| 2026-07-28 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-07-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 86 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-28 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 65-99 mg/dL | Normal | S |
| 2026-07-28 | Cholesterol [Mass/volume] in Serum or Plasma | 138 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-07-28 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 47 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-07-28 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 66 | mg/dL | <=99 mg/dL | Normal | S |
| 2026-07-28 | Triglyceride [Mass/volume] in Serum or Plasma | 124 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-07-28 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-08-25 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-146 mmol/L | Normal | S |
| 2026-08-25 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.3 mmol/L | Normal | S |
| 2026-08-25 | Urea nitrogen [Mass/volume] in Serum or Plasma | 15 | mg/dL | 7-25 mg/dL | Normal | S |
| 2026-08-25 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-08-25 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 88 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-25 | Glucose [Mass/volume] in Serum or Plasma | 93 | mg/dL | 65-99 mg/dL | Normal | S |
| 2026-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-10-27 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-12 | Body height | 165 | cm | S |
| 2026-05-12 | Body weight | 74.6 | kg | S |
| 2026-05-12 | Body mass index (BMI) [Ratio] | 27.4 | kg/m2 | S |
| 2026-05-12 | Systolic blood pressure | 164 | mm[Hg] | S |
| 2026-05-12 | Diastolic blood pressure | 100 | mm[Hg] | S |
| 2026-05-12 | Heart rate | 78 | /min | S |
| 2026-05-12 | Respiratory rate | 16 | /min | S |
| 2026-05-12 | Body temperature | 36.7 | Cel | S |
| 2026-05-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-05-26 | Body height | 165 | cm | S |
| 2026-05-26 | Body weight | 74.4 | kg | S |
| 2026-05-26 | Body mass index (BMI) [Ratio] | 27.3 | kg/m2 | S |
| 2026-05-26 | Systolic blood pressure | 148 | mm[Hg] | S |
| 2026-05-26 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 2026-05-26 | Heart rate | 74 | /min | S |
| 2026-05-26 | Respiratory rate | 16 | /min | S |
| 2026-05-26 | Body temperature | 36.6 | Cel | S |
| 2026-05-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-06-30 | Body height | 165 | cm | S |
| 2026-06-30 | Body weight | 74 | kg | S |
| 2026-06-30 | Body mass index (BMI) [Ratio] | 27.2 | kg/m2 | S |
| 2026-06-30 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-06-30 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-06-30 | Heart rate | 72 | /min | S |
| 2026-06-30 | Respiratory rate | 14 | /min | S |
| 2026-06-30 | Body temperature | 36.6 | Cel | S |
| 2026-06-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-25 | Body height | 165 | cm | S |
| 2026-08-25 | Body weight | 73.4 | kg | S |
| 2026-08-25 | Body mass index (BMI) [Ratio] | 27 | kg/m2 | S |
| 2026-08-25 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-08-25 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-08-25 | Heart rate | 68 | /min | S |
| 2026-08-25 | Respiratory rate | 14 | /min | S |
| 2026-08-25 | Body temperature | 36.6 | Cel | S |
| 2026-08-25 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-27 | Body height | 165 | cm | S |
| 2026-10-27 | Body weight | 73 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 26.8 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 66 | /min | S |
| 2026-10-27 | Respiratory rate | 14 | /min | S |
| 2026-10-27 | Body temperature | 36.5 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-28 | Body height | 165 | cm | S |
| 2026-07-28 | Body weight | 73.6 | kg | S |
| 2026-07-28 | Body mass index (BMI) [Ratio] | 27 | kg/m2 | S |
| 2026-07-28 | Systolic blood pressure | 142 | mm[Hg] | S |
| 2026-07-28 | Diastolic blood pressure | 88 | mm[Hg] | S |
| 2026-07-28 | Heart rate | 72 | /min | S |
| 2026-07-28 | Respiratory rate | 14 | /min | S |
| 2026-07-28 | Body temperature | 36.6 | Cel | S |
| 2026-07-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-21 | Body height | 165 | cm | S |
| 2026-07-21 | Body weight | 72.6 | kg | S |
| 2026-07-21 | Body mass index (BMI) [Ratio] | 26.7 | kg/m2 | S |
| 2026-07-21 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-07-21 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-07-21 | Heart rate | 104 | /min | S |
| 2026-07-21 | Respiratory rate | 16 | /min | S |
| 2026-07-21 | Body temperature | 37.2 | Cel | S |
| 2026-07-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-05-12 | Establishing primary care at 50 after a referee's license examination found high blood pressure: exertional breathlessness and chest tightness while refereeing, an ECG showing left ventricular hypertrophy, cardiovascular risk, money worries and mood, and a cardiology consultation | finished | S |
| 2026-05-26 | Two-week review on the day of the cardiology consultation: the echocardiogram, stress test and calcium score, home blood pressure, a statin, and refereeing | finished | S |
| 2026-06-30 | Seven-week review: home blood pressure, the first weeks back at full cards, symptoms, and a dose increase | finished | S |
| 2026-08-25 | Fifteen-week review: blood pressure after the change of medicine, kidney function and potassium, cholesterol on the statin, and the sick visit | finished | S |
| 2026-10-27 | Twenty-four-week review: blood pressure control, symptoms at work, mood and worry, aspirin, and the plan ahead | finished | S |
| 2026-07-21 | Same-day sick visit for lightheadedness after refereeing in the heat | finished | S |
| 2026-07-28 | Periodic adult preventive visit and recheck after the sick visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| High blood pressure: home monitoring with a validated upper-arm cuff, twice a day, with readings sent in weekly; single-pill losartan 50 mg with hydrochlorothiazide 12.5 mg from today, chosen as two first-line drugs for stage 2 hypertension and a low-cost generic; basic metabolic panel in two weeks; target below 130/80 mmHg; less salt (no more than 1,500 to 2,300 mg a day), the DASH pattern, and regular walking | completed | GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Cardiology consultation for exertional breathlessness and chest tightness with left ventricular hypertrophy on the ECG: the cause, the type of hypertrophy, sudden cardiac death risk, coronary risk testing, and whether he can keep refereeing | completed | GL-CHESTPAIN-2021, GL-AHA-HTN-2025, GL-AHA-CCD-2023 | S |
| Evaluation at intake: resting ECG, basic metabolic panel, TSH, HbA1c, lipid panel, one-time lipoprotein(a) and urine albumin-to-creatinine ratio; stop and rest, and call the same day for chest discomfort at rest or lasting more than a few minutes, fainting or palpitations; referee only short undercards until the consultation | completed | GL-AHA-HTN-2025, GL-CHESTPAIN-2021, GL-ACC-DYSLIP-2026 | S |
| Atorvastatin 40 mg each evening after a coronary calcium score of 186, aiming for LDL below 70 mg/dL and at least a 50% fall, with a lipid panel at eight to twelve weeks; aspirin discussed and not started while blood pressure is uncontrolled, to be revisited | completed | GL-ACC-DYSLIP-2026, GL-AHA-CCD-2023, GL-ACC-PREV-2019 | S |
| Return to work: short undercards until home blood pressure is below 140/90 mmHg, then full cards; drink water between bouts in hot arenas; stop and hand over the bout for chest discomfort, faintness or palpitations; hold the blood pressure tablet on sick days (vomiting, diarrhea, or unable to drink) and call; the venue to keep a defibrillator at ringside with staff trained in CPR; repeat echocardiogram in six to twelve months | completed | GL-ATHLETE-HTN-2015, GL-AHA-HTN-2025 | S |
| Losartan 100 mg with hydrochlorothiazide 25 mg each morning; basic metabolic panel two weeks after the increase | completed | GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Volume depletion: oral fluids with salt and potassium-rich foods; hold losartan-hydrochlorothiazide until the recheck in one week; no refereeing until then; emergency care for fainting or chest pain | completed | GL-AHA-HTN-2025 | S |
| Change to losartan 100 mg and amlodipine 5 mg each morning, without the thiazide, because of heavy sweating in hot arenas; basic metabolic panel in four weeks; written sick-day rules on a card for his wallet | completed | GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Money worries and mood: PHQ-9 and GAD-7 at intake and at six months; generic once-daily medicines at the lowest cost; a social needs screen; brief support and problem-solving at each visit | completed | GL-USPSTF-DEP-2023, GL-USPSTF-ANX-2023 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Find the cause of the exertional breathlessness and chest tightness | 2026-05-26 | completed | No inducible ischemia; symptoms from hypertensive heart disease with an exaggerated blood pressure response | S |
| Blood pressure below 130/80 mmHg at home and in the clinic | 2026-08-25 | completed | 164/100 at intake to 124/78 in the clinic, home average 122/76 mmHg | S |
| LDL below 70 mg/dL and at least 50% lower than at intake | 2026-07-28 | completed | LDL 160 to 66 mg/dL (59% lower) on atorvastatin 40 mg | S |
| Keep refereeing full cards safely, without symptoms | 2027-05-12 | active | Back to full cards after the blood pressure fell; no symptoms since; a week off after the sick visit | S |
| Regression of left ventricular hypertrophy on a repeat echocardiogram | 2027-05-26 | active | Repeat echocardiogram due six to twelve months after the first | S |